IL5 and nasopharyngitis: A comprehensive analysis of clinical data elucidated that the incidence rates of URTI, nasopharyngitis, and sinusitis were commensurate or less in the anti-IL-5 treated group relative to the placebo cohort, subject to comparable relative risks across each therapeutic subgroup.